Skip to main content
NCBI home page
Journal of the Royal Society of Medicine logoLink to Journal of the Royal Society of Medicine
. 1996 Aug;89(8):448–453. doi: 10.1177/014107689608900808

Endocrine treatment of cancer.

T Gulliford 1, R J Epstein 1
PMCID: PMC1295886  PMID: 8795498

Abstract

Cancer has been treated by hormonal manipulation for over 100 years. Although therapeutic progress during this period has resulted mainly from clinical observation, more rational treatment approaches are now emerging from insights into the molecular basis of hormone-responsiveness. Among these are the recognition that hormonal signalling effects are transduced via specific receptor proteins, and the possibility that tumour lysis by hormonal therapies is effected by triggering of a programmed cell death pathway. Clinical progress has already been achieved through basic advances: receptor assays, for example, now permit prediction of treatment benefit in various settings. However, much remains to be learned about the mechanism and application of hormonal anticancer treatments.

Full text

PDF
448

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akakura K., Bruchovsky N., Goldenberg S. L., Rennie P. S., Buckley A. R., Sullivan L. D. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer. 1993 May 1;71(9):2782–2790. doi: 10.1002/1097-0142(19930501)71:9<2782::aid-cncr2820710916>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  2. Borg A., Tandon A. K., Sigurdsson H., Clark G. M., Fernö M., Fuqua S. A., Killander D., McGuire W. L. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990 Jul 15;50(14):4332–4337. [PubMed] [Google Scholar]
  3. Brändström A., Westin P., Bergh A., Cajander S., Damber J. E. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat. Cancer Res. 1994 Jul 1;54(13):3594–3601. [PubMed] [Google Scholar]
  4. Carlson J. A., Jr, Allegra J. C., Day T. G., Jr, Wittliff J. L. Tamoxifen and endometrial carcinoma: alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia. Am J Obstet Gynecol. 1984 May 15;149(2):149–153. doi: 10.1016/0002-9378(84)90187-x. [DOI] [PubMed] [Google Scholar]
  5. Clark O. H. TSH suppression in the management of thyroid nodules and thyroid cancer. World J Surg. 1981 Jan;5(1):39–47. doi: 10.1007/BF01657832. [DOI] [PubMed] [Google Scholar]
  6. Colditz G. A., Hankinson S. E., Hunter D. J., Willett W. C., Manson J. E., Stampfer M. J., Hennekens C., Rosner B., Speizer F. E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995 Jun 15;332(24):1589–1593. doi: 10.1056/NEJM199506153322401. [DOI] [PubMed] [Google Scholar]
  7. Cooper D. S. Clinical review 66: Thyroxine suppression therapy for benign nodular disease. J Clin Endocrinol Metab. 1995 Feb;80(2):331–334. doi: 10.1210/jcem.80.2.7852483. [DOI] [PubMed] [Google Scholar]
  8. Dong F., Brynes R. K., Tidow N., Welte K., Löwenberg B., Touw I. P. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med. 1995 Aug 24;333(8):487–493. doi: 10.1056/NEJM199508243330804. [DOI] [PubMed] [Google Scholar]
  9. Epstein R. J. The clinical biology of hormone-responsive breast cancer. Cancer Treat Rev. 1988 Mar;15(1):33–51. doi: 10.1016/0305-7372(88)90008-4. [DOI] [PubMed] [Google Scholar]
  10. Fuqua S. A., Wolf D. M. Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Res Treat. 1995 Sep;35(3):233–241. doi: 10.1007/BF00665974. [DOI] [PubMed] [Google Scholar]
  11. Garcia M., Derocq D., Freiss G., Rochefort H. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11538–11542. doi: 10.1073/pnas.89.23.11538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Karnik P. S., Kulkarni S., Liu X. P., Budd G. T., Bukowski R. M. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res. 1994 Jan 15;54(2):349–353. [PubMed] [Google Scholar]
  13. Komminoth P., Kunz E. K., Matias-Guiu X., Hiort O., Christiansen G., Colomer A., Roth J., Heitz P. U. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Cancer. 1995 Aug 1;76(3):479–489. doi: 10.1002/1097-0142(19950801)76:3<479::aid-cncr2820760319>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  14. Kyprianou N., English H. F., Isaacs J. T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res. 1990 Jun 15;50(12):3748–3753. [PubMed] [Google Scholar]
  15. Ma Z. Q., Spreafico E., Pollio G., Santagati S., Conti E., Cattaneo E., Maggi A. Activated estrogen receptor mediates growth arrest and differentiation of a neuroblastoma cell line. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3740–3744. doi: 10.1073/pnas.90.8.3740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Maton P. N. The use of the long-acting somatostatin analogue, octreotide acetate, in patients with islet cell tumors. Gastroenterol Clin North Am. 1989 Dec;18(4):897–922. [PubMed] [Google Scholar]
  17. Mortel R., Levy C., Wolff J. P., Nicolas J. C., Robel P., Baulieu E. E. Female sex steroid receptors in postmenopausal endometrial carcinoma and biochemical response to an antiestrogen. Cancer Res. 1981 Mar;41(3):1140–1147. [PubMed] [Google Scholar]
  18. Newmark J. R., Hardy D. O., Tonb D. C., Carter B. S., Epstein J. I., Isaacs W. B., Brown T. R., Barrack E. R. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6319–6323. doi: 10.1073/pnas.89.14.6319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ottaviano Y. L., Issa J. P., Parl F. F., Smith H. S., Baylin S. B., Davidson N. E. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 1994 May 15;54(10):2552–2555. [PubMed] [Google Scholar]
  20. Powles T. J., Hickish T. F., Makris A., Ashley S. E., O'Brien M. E., Tidy V. A., Casey S., Nash A. G., Sacks N., Cosgrove D. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 1995 Mar;13(3):547–552. doi: 10.1200/JCO.1995.13.3.547. [DOI] [PubMed] [Google Scholar]
  21. Sainsbury J. R., Farndon J. R., Sherbet G. V., Harris A. L. Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet. 1985 Feb 16;1(8425):364–366. doi: 10.1016/s0140-6736(85)91385-6. [DOI] [PubMed] [Google Scholar]
  22. Tandon A. K., Clark G. M., Chamness G. C., Ullrich A., McGuire W. L. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989 Aug;7(8):1120–1128. doi: 10.1200/JCO.1989.7.8.1120. [DOI] [PubMed] [Google Scholar]
  23. Taplin M. E., Bubley G. J., Shuster T. D., Frantz M. E., Spooner A. E., Ogata G. K., Keer H. N., Balk S. P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995 May 25;332(21):1393–1398. doi: 10.1056/NEJM199505253322101. [DOI] [PubMed] [Google Scholar]
  24. Vaux D. L. Toward an understanding of the molecular mechanisms of physiological cell death. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):786–789. doi: 10.1073/pnas.90.3.786. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES